CompletedPhase 2NCT02022033
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Studying Intraductal papillary mucinous carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Brown University
- Principal Investigator
- Howard Safran, MDBrUOG
- Intervention
- FOLFOXA(drug)
- Enrollment
- 25 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2022
Study locations (2)
- Roxanne Wood, Providence, Rhode Island, United States
- The Miriam Hospital, Providence, Rhode Island, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02022033 on ClinicalTrials.govOther trials for Intraductal papillary mucinous carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07216521Intent of Surgery for IPMNNYU Langone Health
- RECRUITINGNCT07117045Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic CancerChanghai Hospital
- RECRUITINGNCT06574373Identification of New Theranostic Biomarkers of Pancreatic Tumor ProgressionFondazione Policlinico Universitario Agostino Gemelli IRCCS
- ACTIVE NOT RECRUITINGNANCT06712797Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception CenterH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06694792Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) ConsortiumIRCCS San Raffaele
- ENROLLING BY INVITATIONNCT06276764The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)Adenocyte, LLC
- RECRUITINGNCT06638866AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening CohortChanghai Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06519097Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)H. Lee Moffitt Cancer Center and Research Institute
See all trials for Intraductal papillary mucinous carcinoma of pancreas →